1. Kleines M, Schiefer J, Stienen A, Blaum M, Ritter K, Häusler M. Expanding the spectrum of neurological disease associated with Ep-stein-Barr virus activity. Eur J Clin Microbiol Infect Dis. 2011; 30:1561–1569.
Article
2. Häusler M, Ramaekers VT, Doenges M, Schweizer K, Ritter K, Schaade L. Neurological complications of acute and persistent Epstein-Barr virus infection in paediatric patients. J Med Virol. 2002; 68:253–263.
Article
3. Kennedy M, Apostolova M. A rare case of infectious mononucleo-sis complicated by Guillain-Barre syndrome. Neurol Int. 2013; 5:20–22.
Article
4. Yuki N, Hartung HP. Guillain–Barré syndrome. N Engl J Med. 2012; 366:2294–2304.
Article
5. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990; 27(Suppl):S21–S24.
Article
6. de Paschale M, Clerici P. Serological diagnosis of Epstein-Barr virus infection: problems and solutions. World J Virol. 2012; 1:31–43.
Article
7. Portegies P, Corssmit N. Epstein-Barr virus and the nervous system. Curr Opin Neurol. 2000; 13:301–304.
Article
8. Jacobs B, Rothbarth P, van der Meché F, Herbrink P, Schmitz P, de Klerk M, et al. The spectrum of antecedent infections in Guil-lain-Barre syndrome a case-control study. Neurology. 1998; 51:1110–1115.
9. Torre D, Tambini R. Acyclovir for treatment of infectious mononu-cleosis: a metaanalysis. Scand J Infect Dis. 1999; 31:543–547.
10. Tynell E, Aurelius E, Brandell A, Julander I, Wood M, Yao QY, et al. Acyclovir and prednisolone treatment of acute infectious mono-nucleosis: a multicenter, double-blind, placebocontrolled study. J Infect Dis. 1996; 174:324–331.
Article